Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Peripheral Vascular Disease

Forrest Rubenstein, MD, Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic Surgery
November 21, 2006
DES for acute MI
Analysis of: Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction (content.nejm.org)
Recent studies have demonstrated higher rates of subacute and late stent thrombosis for DES after discontinuation of Plavix compared to bare metal stents and this calls into question the safety of this trend.Drug-eluting stents account for 90% of stents placed in many institutions in the US and Europe....
Analysis of: New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses (newsroom.lilly.com)
The article presents a laboratory assay of platelet inhibition after Prasugrel or Clopidogrel administration. The findings are that Prasugrel achieves faster and more effective inhibition of platelets compared with Clopidogrel using an in vitro assay. The implication is that Prasugrel should be more...
Forrest Rubenstein, MD, Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic Surgery
Analysis of: AHA Scientific Sessions - Percutaneous Devices for Aortic Valve Disease (www.cardiosource.com)
Percutaneous valves have been in development for several years.There are 2 percutaneous valves in clinical trials now - Edwards PVT valve and the Corevalve product.At this time, they are only indicated for patients deemed too sick for standard valve replacement or those with a life - limiting disease...
Forrest Rubenstein, MD, Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic Surgery
Analysis of: Chocoholics rejoice! More benefits found in heart study (www.cnn.com)
Americans spend billions of dollars yearly on medications to treat or prevent diseases of self abuse.Coronary artery disease, diabetes, hypertension, obesity, COPD and cancer are all caused by or exacerbated by lifestyle choices or habits that we choose.Articles such as this remind us that moderation...
Forrest Rubenstein, MD, Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic Surgery
Analysis of: Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity (www.drugdevelopment-technology.com)
Rimonabant is a novel CB1 inhibitor which blocks the endogenous endocannibinoid receptor that leads to overeating.Rimonabant has been shown to cause a much greater weight loss than previous medications without any of the serious side effects seen with them to date.These results have been sustained for...
Forrest Rubenstein, MD, Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic Surgery
Analysis of: Pay-for-Performance Plans Now Common Among HMOs (www.nlm.nih.gov)
Pay for performance sounds wonderful - who doesn't want their doctors to practice the best possible medicine?The concept of paying more to those physicians who have the best outcomes and to stimulate those with worse outcomes to improve also seems beneficial.Compliance with established guidelines and...
Forrest Rubenstein, MD, Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic Surgery
November 13, 2006
MRSA control
Analysis of: Dutch "Search and Destroy" Policy Keeps Community-Acquired MRSA in Check (www.medscape.com)
MRSA which was previously only a hospital acquired infection is now rampant in several communities and present in almost all.Many patients enter the hospital as carriers and develop invasive disease or pass the bacterium to other susceptible patients.This strain of MRSA is particularly virulent and...
Forrest Rubenstein, MD, Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic Surgery
Analysis of: Pfizer Updates Preliminary Results Of Torcetrapib/Atorvastatin Clinical Trials As Abstract For Phase 3 Study Is Released (www.medicalnewstoday.com)
The mainstay of treatment for hypercholesterolemia now is a statin drug (HMG CoA reductase inhibitor) to reduce LDL levels.These statin drugs have been proven to reduce LDL cholesterol and to reduce cardiac events.Another major independent cardiovascular risk factor is low levels of HDL cholesterol...
Analysis of: Pfizer Updates Preliminary Results Of Torcetrapib/Atorvastatin Clinical Trials As Abstract For Phase 3 Study Is Released (www.medicalnewstoday.com)
It has become increasingly clear that the FDA requires "clinically relevant" endpoints for approval of cardiovascular drugs and devices.
Forrest Rubenstein, MD, Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic Surgery
Analysis of: Northfield Laboratories, Inc. Reports First Quarter Fiscal 2007 Financial Results (phx.corporate-ir.net)
The importance of this article has nothing to do with this quarter's earnings - the importance is the soon to be released trial results on PolyHeme.PolyHeme, a hemoglobin solution that acts as a blood substitute for trauma patients, can be stored with a shelf life > 1 year and requires no refrigeration.Because...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next91 to 100 of 107

Analytics


Generated at 2009-01-07T19:00:58.307